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Abstract
Cancer is a leading cause of death of men and women worldwide. Tumor cell motility contributes to metastatic invasion
that causes the vast majority of cancer deaths. Extracellular receptors modified by a2,3-sialic acids that promote this motility
can serve as ideal chemotherapeutic targets. For example, the extracellular domain of the mucin receptor podoplanin
(PDPN) is highly O-glycosylated with a2,3-sialic acid linked to galactose. PDPN is activated by endogenous ligands to induce
tumor cell motility and metastasis. Dietary lectins that target proteins containing a2,3-sialic acid inhibit tumor cell growth.
However, anti-cancer lectins that have been examined thus far target receptors that have not been identified. We report
here that a lectin from the seeds of Maackia amurensis (MASL) with affinity for O-linked carbohydrate chains containing sialic
acid targets PDPN to inhibit transformed cell growth and motility at nanomolar concentrations. Interestingly, the biological
activity of this lectin survives gastrointestinal proteolysis and enters the cardiovascular system to inhibit melanoma cell
growth, migration, and tumorigenesis. These studies demonstrate how lectins may be used to help develop dietary agents
that target specific receptors to combat malignant cell growth.
Citation: Ochoa-Alvarez JA, Krishnan H, Shen Y, Acharya NK, Han M, et al. (2012) Plant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by
Podoplanin, to Inhibit Transformed Cell Growth and Migration. PLoS ONE 7(7): e41845. doi:10.1371/journal.pone.0041845
Editor: Jonas Fuxe, Karolinska Institute, Sweden
Received November 16, 2011; Accepted June 29, 2012; Published July 23, 2012
Copyright:  2012 Ochoa-Alvarez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from the NIH (R01CA126897) to J-GG, the Ministry of Education, Culture, Sports, Science and Technology of Japan
to TS, and the Research Foundation of UMDNJ, the Northarvest Bean Growers Association, and Sentrimed to GSG. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Dr. Goldberg and Dr. Temiakov are scientific advisors and shareholders of Sentrimed, which has funded part of this work and supplied the
reagent MASL. Dr. McNulty is an employee of GlaxoSmithKline. There are no patents, products in development or marketed products to declare. This does not
alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: gary.goldberg@umdnj.edu
. These authors contributed equally to this work.
Introduction
Over 1 in 4 people are diagnosed with cancer at some point in
their life [1]. These cancers are the leading cause of death of men
and women under 85 years old [2]. Tumor cell motility con-
tributes to metastatic invasion that causes the vast majority of
cancer deaths [3,4]. Extracellular receptors that promote this
motility can serve as ideal chemotherapeutic targets [5–9]. Ex-
pression levels of receptors with a2,3-sialic acid residues are closely
associated with the invasive and metastatic potential of many
cancers [10–12] including skin cancer [13,14]. Podoplanin (PD
PN) represents one of these receptors.
PDPN is a unique transmembrane receptor that promotes
tumor cell motility. PDPN expression can be induced by tumor
promoters including TPA, oncogenic Ras, and Src [15–17]. For
example, we have reported that Src utilizes the focal adhesion
adaptor protein Cas to induce PDPN expression in order to
promote tumor cell migration [15]. PDPN regulates the activities
of effectors including ezrin, Rho, and Cdc42 to mediate filopodia
formation and promote tumor cell migration, invasion, and
metastasis [5,18–22].
PDPN is found at the invasive front of many tumors, which is
consistent with its role in promoting malignant invasion [5,20,23].
For example, PDPN expression is strongly induced in about 40%
of breast cancers [20,24], 50% of oral cancers [23,25,26], and
80% of skin cancers [27,28]. The bulk of the PDPN protein, about
150 amino acids, lies outside of the cell and could serve as an ideal
target to combat cancer invasion and metastasis [5,29].
The extracellular domain of PDPN is highly O-glycosylated with
sialic acid, a2,3 linked to galactose [5,30]. PDPN is activated by
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endogenous ligands that bind to these extracellular carbohydrate
moieties [31–33] to induce tumor cell motility and metastasis
[20,33–35]. Thus, blocking this interaction should inhibit malig-
nant progression. For instance, compounds blocking the action of
galectins, which activate mucin receptors, can inhibit tumor cell
metastasis [36,37].
Antibodies against PDPN can inhibit lung metastasis of tran-
sformed cells that express PDPN [38,39]. However, antibody
therapy presents challenges in administration and toxicity [40,41].
Since PDPN is modified by a2,3-sialic acid, it can be targeted by
specific lectins [10,12–14,42].
Unlike antibodies, lectins can survive digestive processing and
retain biological activity [43–46]. Indeed, dietary lectins can block
the action of endogenous pro-metastatic lectins (such as galectins
or selectins) to inhibit tumor cell growth [37,45–47]. For example,
although its targets and mechanisms are not yet defined, Mistletoe
lectin (viscumin) binds proteins containing a2,3-sialic acid, has
undergone successful clinical trials, and is widely used to treat
melanoma in Europe [48–50]. However, anti-cancer lectins that
have been examined thus far target receptors that have not been
identified.
Here, we show that a lectin with affinity for O-linked carbo-
hydrate chains containing sialic acid binds to PDPN to inhibit
transformed cell growth and motility at submicromolar concen-
trations. This approach demonstrates how lectins may be used as
dietary agents that target specific receptors to combat malignant
cell growth.
Results
MASL targets PDPN on Src transformed cells
We have recently reported that the Src tyrosine kinase utilizes
the adaptor protein Cas/BCAR1 to augment PDPN expression in
order to promote tumor cell motility [15]. PDPN is also pro-
foundly involved in the ability of transformed cells to escape
contact normalization (growth control by surrounding nontrans-
formed cells) and ‘‘break out’’ of their microenvironment to
become malignant or metastatic [15]. Consistent with these pre-
vious reports, Src transformed cells expressed more PDPN (see
Figure 1a and 1b) and migrated more than nontransformed
controls (Figure 1c). As described above, the extracellular domain
of PDPN is O-glycosylated with sialic acid, a2,3 linked to ga-
lactose. Scholl et al have reported that PDPN associates with lectin
from seeds of the legume tree Maackia amurensis (MASL) [30],
which has an affinity for O-linked carbohydrate chains containing
sialic acid [51,52]. These observations led us to investigate the
ability of MASL to target PDPN on transformed cells.
As shown in Figure 2a, MASL associated with PDPN on the
membrane of Src transformed cells. Note that MASL did not
target the membrane of cells that did not express PDPN, which,
along with functional studies described below, attests to its pre-
ferential targeting. In addition, MASL associated with PDPN in
lysates from transformed cells during affinity precipitation ex-
periments as shown in Figure 2b.
MASL inhibits Src transformed cell growth and migration
We hypothesized that binding of MASL to PDPN would inhibit
transformed cell migration. As shown in Figure 2c, MASL sig-
nificantly inhibited transformed cell migration, with 385 nM and
770 nM inhibiting cell migration by over 25% and 50%
respectively. In contrast, MASL did not inhibit the migration of
nontransformed cells in a dose dependent fashion at these con-
centrations.
To verify the functional relevance of MASL targeting PDPN on
cell migration, we investigated its effects on nontransformed cells
transfected with PDPN or empty parental vector. Since PDPN
expression is sufficient to promote cell migration [5,15,30], non-
transformed cells transfected with PDPN migrated several fold
more than control transfectants (Figure 3a and 3b). In addition,
MASL reduced the migration of these nontransformed PDPN
transfected cells in a dose dependent fashion (Figure 3b). For
example, 385 nM MASL decreased the migration of PDPN
transfectants by over 40%.
As shown in Figure 3c, in addition to inhibiting cell migration,
MASL was also toxic to PDPN expressing cells in a dose de-
pendent fashion. In contrast, MASL did not inhibit the viability of
empty vector transfectants in an equally dose dependent fashion.
For example, 1540 nM MASL decreased Trypan blue exclusion of
PDPN transfectants by over 70%, but control transfectants by only
about 30%.
MASL targets PDPN to inhibit melanoma cell growth and
motility
Studies indicate that PDPN expression is strongly induced in
about 80% of skin cancers [27,28]. Consistent with its role in
tumor cell invasion and metastasis, malignant B16 melanoma cells
expressed higher levels of PDPN (Figure 4a) and migrated
significantly better (Figure 4b) than syngeneic nontransformed
Melan-a melanocytes. As shown in Figure 4c, MASL effectively
suppressed melanoma cell migration at concentrations of 308 nM
Figure 1. Src activation induces Pdpn expression and cell migration. (a) PDPN, active Src kinase (phosphorylated at Y-416), and b-actin were
detected by Western blotting of protein (20 mg per lane) from LA-25 cells (NRK cells containing temperature sensitive v-Src) grown overnight at 33uC
(permissive temperature) or 40uC (non-permissive temperature). (b) PDPN, active Src (phosphorylated at Y416), and b-actin were detected by Western
blotting of protein (15 mg per lane) from nontransformed cells or Src transformed mouse embryonic cells (MEFs) as indicated. (C) Wound healing
migration assays were performed on confluent monolayers of Src transformed or nontransformed cells. Data are shown as the number of cells that
migrated into a 3006300 micron area along the center of the wound in 24 hours (mean + SEM, n = 7). Double asterisks indicate p,0.01 compared to
untreated Src controls.
doi:10.1371/journal.pone.0041845.g001
Targeting Podoplanin on Transformed Cells
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or less. In addition to inhibiting melanoma cell migration, MASL
also inhibited melanoma cell growth in a dose responsive manner
(Figure 4d). Moreover, MASL was significantly more toxic to
B16 melanoma cells than Melan-a cells (p,0.001 by ANOVA).
Transwell chambers were used to further investigate the effects
of MASL on melanoma cell growth and migration. As shown in
Figure 4e, while 385 nM MASL was not significantly toxic to
B16 melanoma cells (p.0.2 compared to controls), migration
through 8 micron pores was decreased by over 40 fold. These data
indicate that MASL suppressed melanoma cell migration prior to
inhibiting cell viability.
We employed siRNA to verify the effects of PDPN and MASL
on melanoma cell growth and migration. PDPN siRNA effectively
decreased B16 Pdpn expression levels (Figure 5a) and cell
migration (Figure 5b). As shown in Figure 5c, this decreased
PDPN expression resulted in a 25% decrease in MASL toxicity.
These data indicate that while PDPN may not be the only receptor
targeted by MASL on these melanoma cells, it is a functionally
relevant receptor that can be targeted to prevent melanoma cell
growth and migration.
MASL may induce caspase independent necrosis of
melanoma cells
Some lectins used as potential anticancer agents, including Mist-
letoe lectins, contain a distinct N-glycosidase motif that acts as a
ribosome inactivating peptide (RIP) [45]. Since MASL does not
contain this peptide, inhibition of tumor cell viability by MASL
did not result from RIP activity. In general, cell death can occur by
apoptosis, necrosis, or autophagy [53,54]. MASL did not induce
characteristics of autophagy such vacuolarization or the formation
of autophagosomes, or characteristics of apoptosis including nu-
clear chromatin condensation, membrane blebbing, or chromo-
somal DNA fragmentation. Instead, MASL induced morpholog-
ical changes typical of necrosis including cell swelling, membrane
rupture, and nuclei fragmentation.
Apoptosis usually results from the induction of caspase activity
which cleaves poly(ADP-ribose) polymerase (PARP) into an 89 kD
fragment [55,56]. As shown in Figure 6, while PARP cleavage
was clearly detected in cells treated with puromycin which induces
caspase mediated apoptosis [57], only slight PARP cleavage was
seen in melanoma cells treated with MASL (p.0.2 by ANOVA).
Figure 3. MASL targets PDPN to decrease cell migration and viability. (a) PDPN and b-actin were detected by Western blotting of protein
(15 mg per lane) from nontransformed mouse embryonic cells (MEFs) transfected with cDNA encoding PDPN or empty parental vector (EF4) as
indicated. (b) Wound healing migration assays were performed on confluent monolayers treated with concentrations of MASL as indicated. Data are
shown as the number of cells that migrated into a 3006300 micron area along the center of the wound in 24 hours (mean + SEM, n = 7). (c) MASL
toxicity was evaluated by Trypan blue staining of cells, and shown as the percent of live cells from each well (mean + SEM, n = 4). Single and triple
asterisks indicate p,0.05 and p,0.001, respectively, compared to untreated controls.
doi:10.1371/journal.pone.0041845.g003
Figure 2. MASL associates with PDPN and inhibits migration of Src transformed cells. (a) Src transformed cells were exposed to MASL
conjugated to HiLyte Fluor TR (red), and PDPN was detected by immunofluorescence microscopy (green). Colocalization of lectin and PDPN (yellow)
is apparent in merged images, including orthogonal views of the z-axis which is 14 microns thick (bar = 20 microns). (b) Protein from Src transformed
cells (750 mg) was precipitated with agarose beads linked to MASL, or control beads, and examined for PDPN by Western blotting. Cell lysate (15 mg/
lane) were also examined as indicated. (c) Wound healing migration assays were performed on confluent monolayers of cells treated with
concentrations of MASL as indicated. Data are shown as the number of cells that migrated into a 300x300 micron area along the center of the wound
in 24 hours (mean + SEM, n = 7). Double asterisks indicate p,0.01 compared to nontransformed cells.
doi:10.1371/journal.pone.0041845.g002
Targeting Podoplanin on Transformed Cells
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These observations suggest that MASL can reduce tumor cell
growth by caspase independent necrotic mechanisms. This property
may be particularly advantageous when applied to malignancies
that resist apoptosis induced by classical cancer agents.
Dietary MASL inhibits melanoma cell migration and
tumorigenesis
As described above, some dietary lectins can survive digestive
processing to combat cancer in vivo [43–46]. Serum was taken from
mice fed MASL and then examined for its effects on melanoma
cell migration in vitro to determine if this dietary lectin can survive
gastrointestinal proteolysis to remain biologically active in the
circulatory system. As shown in Figure 7, serum from mice fed
100 or 200 mg/kg MASL inhibited melanoma cell migration by
about 30% or over 80% compared to serum from mice fed no
MASL, respectively. These data indicate that dietary administra-
tion of MASL can result in biologically relevant levels of
circulating product that are sufficient to inhibit melanoma cell
migration.
Figure 4. MASL inhibits melanoma cell motility and viability. (a) PDPN and b-actin were detected by Western blotting of protein (15 mg per
lane) from Melan-a melanocytes and B16 melanoma cells. (b) Wound healing migration assays were performed on confluent MelanA and B16
monolayers. Data are shown as the number of cells that migrated into a 4006500 micron area along the center of the wound in 24 hours (mean +
SEM, n = 5). (c) Wound healing migration assays were performed on confluent monolayers treated with MASL as indicated. Data are shown as the
number of cells that migrated into a 4006500 micron area along the center of the wound in 24 hours (mean + SEM, n = 5). (d) Melan-a and B16 cells
were treated with MASL, and cell viability was evaluated by Alamar blue assay. Data are shown as percent of nontreated cells (mean + SEM, n = 2). (e)
Melanoma cell viability and Transwell migration assays were performed on 600,000 cells plated on cell culture inserts containing membranes with an
8 micron pore size in 6-well plates. Cell viability was evaluated by Alamar blue assay and shown as percent of nontreated cells, while Transwell
migration was measured after 24 hours as the percent of cells found on the underside of the membrane (mean + SEM, n = 2). Double and triple
asterisks indicate p,0.01 and p,0.001 compared to corresponding treatments of untreated cells or Melan-a cells in panels d and e, respectively.
doi:10.1371/journal.pone.0041845.g004
Targeting Podoplanin on Transformed Cells
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Since MASL, or at least its biological activity, was resistant to
gastrointestinal proteolysis we examined the effects of dietary
MASL on tumor cell growth in vivo. As shown in Figure 8a, oral
administration of 25 mg/kg of MASL once a week inhibited the
subcutaneous growth of melanoma cells in mice by approximately
50% (p,0.05 by ANOVA). Moreover, we found no adverse effects
on mouse health or physiology over the course of these ex-
periments based on animal behavior, weight, and organ analysis
after dissection.
As expected, PDPN expression was evident in melanoma cells of
tumors in vivo. As shown in Figure 8b, PDPN expression was
more intense in tumor cells from control animals than animals
treated with MASL. In addition, tumor cells from MASL treated
animals appeared more epithelial in nature, with a relatively
flattened morphology and more restricted PDPN staining than
tumors from untreated animals.
Dietary MASL inhibits the formation of blood channels
lined by melanoma cells
Although its molecular target has not been defined, Mistletoe
lectin is used as an anticancer agent that can reduce tumor
vascularization in vivo [46,58,59]. Aggressive melanoma cells are
known for their ability to form blood vessels lined with tumor cells
by a process referred to as ‘‘vasculogenic mimicry’’ [60]. Inte-
restingly, as shown in Figure 8b and 8c, these blood filled
vascular spaces lined by tumor cells were much smaller and less
Figure 5. MASL targets PDPN to inhibit melanoma cell growth. (a) PDPN and b-actin were detected by Western blotting of protein (5 mg per
lane) from B16 melanoma cells transfected with control siRNA or siRNA targeted against PDPN, as indicated. (b) Wound healing migration assays
were performed on confluent B16 monolayers transfected with control siRNA or siRNA targeted against PDPN, as indicated. Data are shown as the
number of cells that migrated into a 5006400 micron area along the center of the wound in 24 hours (mean + SEM, n = 4). (c) MASL toxicity was
evaluated by Trypan blue staining of cells, and shown as the percent of live cells from each well (mean + SEM, n = 2). Single, double, and triple
asterisks indicate p,0.05, p,0.01, and p,0.001, respectively, compared to nontransformed cells, untreated Src transformed cells, or control
transfectants as indicated.
doi:10.1371/journal.pone.0041845.g005
Figure 6. Effects of MASL on PARP cleavage. (top) PARP and b-
actin were examined by Western blotting of protein from B16
melanoma cells treated for 24 hours with MASL or 37 mM puromycin
as indicated. (bottom) Signal was quantitated by image densitometry
(NIH Image) and shown as the percent of cleaved PARP compared to
total PARP (mean + SEM, n = 2).
doi:10.1371/journal.pone.0041845.g006
Figure 7. Dietary MASL bioactivity survives gastrointestinal
proteolysis to enter the cardiovascular circulatory system and
inhibit melanoma cell migration. Wound healing migration assays
were performed on confluent monolayers of B16 melanoma cells
treated with serum from mice fed MASL to achieve doses of 1, 100 mg/
kg, or 200 mg/kg, or without mouse serum (controls) as indicated. Data
are shown as the number of cells that migrated into a 2006300 micron
area along the center of the wound in 24 hours (mean + SEM, n = 7).
Triple asterisks indicate p,0.001 compared to controls.
doi:10.1371/journal.pone.0041845.g007
Targeting Podoplanin on Transformed Cells
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numerous in tumors from MASL treated mice than from control
animals.
Human melanoma cells express PDPN and respond to
MASL
We examined cell lines and clinical specimens to further in-
vestigate PDPN expression and MASL sensitivity in human me-
lanoma cells. As shown in Figure 9a, PDPN expression was
drastically increased in primary and metastatic melanoma speci-
mens from every patient that we examined. As with mouse me-
lanoma cells, PDPN expression was also much higher in human
melanoma cell lines than normal skin. In addition, as with mouse
cells, MASL significantly suppressed human melanoma cell growth
and migration at concentrations of less than 300 nM (Figure 9b
and 9c). Moreover, as with mouse cells, MASL inhibited human
melanoma cell motility prior to effecting cell growth. For example,
308 nM MASL inhibited HT-144 cell migration by over 10 fold,
but cell growth by less than 40%.
MASL consists of 2 subunits of identical primary amino
acid sequence
Lectins are a complex family of proteins. MASL is a tetramer
formed by 32 kD and 37 kD subunits. The 32 kD subunit is called
Maackia amurensis hemagglutinin (MAH) and the 37 kD subunit is
called Maackia amurensis leukoagglutinin (MAL) or Maackia amurensis
mitogen (MAM) [52,61,62]. LC-MS-MS analysis shown in
Figure 10 indicates that both of these subunits consist of the
same primary amino acid sequence that contains a single cysteine
toward the carboxyl terminal at position 243. Unique molecular
weights and other properties of these subunits are likely due to
specific modifications including asparagine glycosylation and de-
amidation events. The presence of a cysteine residue in MASL has
been reported for the 37 kD subunit (MAL) [62]. In contrast,
sequences reported for the 32 kD subunit (MAH) do not contain a
cysteine, but contain a serine in its place [52,61,62]. Our finding
that both 32 kD and 37 kD subunits contain this cysteine explains
their dimerization into respective 64 kD and 74 kD subunits.
Discussion
Lectins are promising anticancer agents that can be administered
orally [47,50]. For example, dietary Mistletoe lectin has been shown
to inhibit lymphoma growth in mice and is used as an adjuvant
therapy to treat various forms of cancer in people [43,59]. Plant
lectins are resistant to gastrointestinal proteolysis and breakdown by
gut bacteria. Wang et al have shown that intact and bioactive
peanut agglutinin (PNA) reaches concentrations of approximately
50nM in the serum of people within hours after ingesting 200g of
peanuts [63]. Our data indicate that similar levels of lectin, or its
bioactive digestion products, may be achieved from ingestion of
MASL. These results also indicate that properties of MASL may be
used to help develop reagents to prevent or combat melanoma.
Melanoma cell motility contributes to metastatic invasion that
causes the vast majority of skin cancer deaths [4]. Robust PDPN
expression was found 100% of the 8 melanoma samples examined
from cancer patients in this study (see Figure 9a). These data are
in contrast to previous studies reporting PDPN expression in less
than 20% of spindle cell and other types of melanomas [64,65].
This may be the result of different experimental methods. For
example, the NZ1 antibody used here targets an approximately 12
amino acid epitope in the PDPN PLAG domain with a
dissociation constant (KD) below 1 nM, while antibody used for
these previous studies targets a larger epitope with lower affinity
[66,67]. However, PDPN staining seen in our patient samples may
Figure 8. Dietary MASL inhibits melanoma growth in vivo. (a)
Mice were fed MASL to achieve a dosage of 0 or 25 mg/kg once weekly
(indicated by asterisks) and inoculated subcutaneously with B16
melanoma cells (100,000 cells per mouse on day indicated by arrow).
Tumors were measured daily by caliper, and data is shown as cubic cm
(mean + SEM, n = 4). (b) Tumors were evaluated for PDPN expression by
IHC as indicated (bar = 50 microns). ‘‘bc’’ indicates blood filled vascular
spaces lined by tumor cells. (c) Tumors were examined by hematoxylin
and eosin staining (H&E) to visualize vascularization and morphology.
(c) Tumor vascularization was quantified as the percent of each field
(0.8 mm2) occupied by blood vessels and shown as mean + SEM (n = 7).
doi:10.1371/journal.pone.0041845.g008
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have been due to cancer associated fibroblasts (CAFs), which
would not be distinguished from actual melanoma cells by
Western blotting. Indeed, PDPN expression in CAFs has been
correlated with tumor aggression in cancers including mammary
carcinoma [68] and lung adenocarcinoma [69–71]. In any case,
robust PDPN expression was seen in all of the melanoma cell lines
that we examined, indicating that melanoma cells themselves
express PDPN (see Figures 4 and 9).
Dietary lectins can block the action of endogenous pro-
metastatic lectins (such as galectins or selectins) to inhibit tumor
cell growth, and can be used as medicinal cancer treatments
[37,45–47]. While MASL has been shown to decrease viability of
different types of transformed cells including melanoma [72,73], its
targets and effects on cell migration have not been reported. Our
data indicate that MASL be used to target PDPN in order to
combat tumor cell growth and migration. Consistent with PDPN
acting as a functionally relevant target, these results indicate that
MASL inhibits cell motility prior to inhibiting cell viability. For
example, 308 nM MASL suppressed melanoma cell migration by
over 99%, while inhibiting cell viability by about 20% within the
same time period (see Figure 4).
Although some lectins may nonspecifically bind to many gly-
coproteins, experiments with cloned Maackia amurensis lectin
indicate that it can accurately target specific glycoproteins ex-
pressed by human cells [74,75]. Our data indicate that MASL,
which has a high affinity for O-linked carbohydrate chains con-
taining sialic acid [51,52], targets PDPN to inhibit transformed cell
growth and motility at nanomolar concentrations. Interestingly,
Maackia amurensis has been used as a medicinal plant for several
centuries to treat ailments including cancer in parts of Asia
[76,77]. However, as with many traditional medicines, clinical
efficacy has been hindered by a lack of mechanistic understanding.
Here, we describe how MASL can serve as a potent bioactive
plant medicine that targets PDPN to combat cancer.
PDPN expression is relatively low in most normal cells, and
found predominantly in tissues including retina, kidney podocytes,
lymphatic endothelium, and lung alveolar epithelium [5,78].
Indeed, as shown in Figure 11, PDPN expression in normal
tissues is somewhat similar to that of VEGFR2 which serves as a
useful chemotherapeutic target [79,80]. Interestingly, PDPN and
VEGFR2 are both receptors that promote cell migration and are
suppressed during contact normalization by surrounding non-
transformed cells in the microenvironment [15].
Our data demonstrate that MASL targets PDPN to inhibit
tumor cell growth and motility. However, MASL is bound to
target other receptors containing similar sialic acid motifs. In
addition, like other reagents, MASL may produce ‘‘off target’’
effects in a clinical setting. However, lectin pharmacology is
complex and MASL may undergo enzymatic modification to form
bioactive compounds in vivo. For example, although legumes in-
cluding lentils and peanuts contain significant amounts of ag-
glutinating lectins, their ingestion does not result in toxic platelet
aggregation [50]. Moreover, MASL caused no notable toxic effects
on organ morphology or animal behavior in our studies which
followed mice treated for about 3 weeks. As stated above, Maackia
amurensis has been used as a medicinal plant for several centuries to
treat ailments including cancer in parts of Asia [76,77]. These
treatments would result in oral administration of hundreds of mg
Figure 9. Human melanoma cells express PDPN and respond to
MASL. (a) PDPN was detected by Western blotting of protein (15 mg
per lane) from a variety of human specimens including normal skin,
primary melanoma, melanoma in transit prior to lymph node
metastasis, nodal metastasis, lung metastasis, and three melanoma
cells lines (HT-144, SK-MEL-2, SK-MEL-5). Detection of MAPK and
nonspecific bands by Western blotting and India ink staining of
membranes is also shown to verify equal loading of these samples from
different patients and cell lines. (b) Wound healing migration assays
were performed on confluent HT-144 monolayers treated with MASL as
indicated. Data are shown as the number of cells that migrated into a
4006500 micron area along the center of the wound in 24 hours (mean
+ SEM, n = 5). (d) HT-144 cells were treated with MASL, and cell viability
was evaluated by Alamar blue assay. Data are shown as percent of
nontreated cells (mean + SEM, n = 2). Single, double, and triple asterisks
indicate p,0.05, p,0.01, and p,0.001 compared to untreated cells,
respectively.
doi:10.1371/journal.pone.0041845.g009
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of MASL per dosage, and have not resulted in reports of toxicity
[81]. However, future studies will clearly be needed to further
investigate the potential toxic effects of MASL or other lectins that
may be considered for clinical use.
Taken together, results from this study suggest that lectins
exemplified by MASL could significantly expand our limited
arsenal of targeted cancer treatments, particularly anticancer
agents that can be administered orally. This paradigm may lead to
novel skin cancer treatments, and pave the way to treat other
cancers with elevated PDPN expression levels including breast
[20,24], glioma [21], and oral cancer [25,26]. However, as stated
above, while PDPN served as the model target of this investigation,
other receptors with a2,3-sialic acid residues are increased in
melanoma and a variety of other cancers, and may also be
targeted to some extent by MASL [10,12–14,42].
Materials and Methods
Ethics Statement
Use of mice to obtain serum was approved by Committee of
Animal Experiment in Nagoya University Graduate School of
Medicine (Approved ID: 23132). Mouse experimental protocols
were approved by the University of Medicine and Dentistry
School of Osteopathic Medicine Institutional Animal Care and
Use Committee (Approved ID: 10350).
Cell culture
Mouse embryonic cells transfected with v-Src, PDPN, or empty
parental vectors have been previously described [15]. LA25 cells
harboring a temperature sensitive v-Src construct were grown as
described [82]. B16F10, SK-MEL-2, SK-MEL-5, and HT-144
melanoma cells were obtained from ATCC. Melan-a melanocytes
were provided by Richard Niles [83]. Clones were not taken from
any cell lines, thus minimizing potential effects of clonal variation.
To knockdown Pdpn expression in B16 cells, cells were transfected
with 200nM of nontargeting control siRNA (Dharmacon D-
001810-10-05) or 200nM podoplanin siRNA (Dharmacon L-
048117-01-0005) with Lipofectamine 2000 (Invitrogen 11668-027)
as described [15]. For some experiments, cells were treated with
MASL (Sigma L8025, Sentrimed MASL) or puromycin (Sigma
P8833).
Western blotting
Human tissue collected by the Honest Broker Program was
excised and flash frozen in liquid nitrogen at the time of excision
during surgery. Western blotting was performed as previously
described [15,84–86]. Protein was resolved by SDS-PAGE, tran-
sferred to Immobilon-P membranes (Millipore IH1079562), and
incubated with antisera specific for PDPN (Sigma NZ1 P0085,
Santa Cruz Biotechnology SC23564, or University of Iowa
Developmental Studies Hybridoma Bank 8.1.1), active Src kinase
(Cell Signaling Technology 2101), PARP (Cell Signaling Tech-
nology 9542), MAPK (Cell Signaling Technology 9102), or ß-actin
(Sigma A1978). Primary antiserum was recognized by appropri-
ate secondary antiserum conjugated to horseradish peroxidase
and detected using Enhanced Chemiluminescence (Millipore
WBKLS0500 or Thermoscientific 32106). After blotting, mem-
Figure 10. Analysis of MASL protein subunits. (a) MASL from Sigma (lane 1) or Sentrimed (lane 2) was analyzed by reducing and nonreducing
SDS-PAGE. (b) Coomassie stained bands were excised, extracted and digested with trypsin, reduced and alkylated with iodoacetamide, and
sequenced using data dependent acquisition by LC-MS/MS on a Thermo Scientific LTQ Orbitrap XL. All peptides were identical in primary sequence
and contained a single cysteine at residue 243 (bold in figure).
doi:10.1371/journal.pone.0041845.g010
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branes were stained with India ink to verify equal loading and
transfer.
Immunofluorescence microscopy
Cells (300,000 per dish) were cultured on 35-mm poly-D-lysine–
coated glass-bottomed culture dishes (MatTek P35GC-1.5-14-C) for
24 hours. MASL was conjugated to Hilyte Fluor TR (Anaspec
72052) and incubated with cells for 15 min at 37uC. Cells were fixed
with 2% paraformaldehyde, permeabilized with 0.2% Triton X-100
in PBS for 10 minutes, washed thrice with 0.1% Tween 20 in PBS
followed by 1% bovine serum albumin (BSA) in PBS for 30 minutes,
incubated with PDPN antiserum (1:100) overnight at 4uC, washed,
and then labeled with goat anti-syrian hamster IgG conjugated to
Alexa Fluor 488 (Molecular Probes A21110). Cells were visualized
on a Zeiss Axiovert microscope as described [15,85].
Affinity precipitation
Cells were lysed in lysis buffer (20 mM Tris.Cl pH 7.4, 150 mM
NaCl, 0.5% Triton X-100, 1mM PMSF) on ice for 30 min, clarified
by centrifugation, diluted to 1 mg/ml in PBS supplemented with
Figure 11. Comparison of Pdpn and Vegfr2 (Kdr) mRNA expression in human tissues. Values from Affymetrix probe sets representing
Pdpn and Vegfr2 are shown as presented on BioGPS (http://biogps.gnf.org).
doi:10.1371/journal.pone.0041845.g011
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1mM PMSF and 10 mM MgCl2, and incubated with MASL
conjugated to agarose beads, or empty beads as controls (Thermo
Scientific 20501), on ice for 3 hours. Beads were then washed
4 times with PBS, and eluted in SDS-PAGE sample buffer at 95uC
for 5 minutes. Eluted protein was examined along with total cell
lysates by Western blotting.
Cell migration and toxicity assays
Cell monolayers were scratched and incubated with MASL for
24 hours to assess cell migration by wound healing assays, which
were quantitated as the number of cells that entered an area of the
wound indicated in Figure Legends as described [15,84,85].
Alamar blue (Invitrogen DAL1025) was added to cells 24 hours
after MASL treatment, and incubated for an additional 8 hours to
assay viability, which was detected by fluorescence measurements
(ex/em 570/600 nm) as directed by the manufacturer (Invitrogen)
in a Tecan GENios microplate fluorescence spectrophotometer.
Cells were also stained with 0.2% trypan blue and counted with a
hemocytometer to evaluate cytotoxicity. For Transwell migration
assays, 600,000 cells were plated in 6-well cluster plates on cell
culture inserts with an 8 micron pore size (Transwell-Clear,
Costar) and grown for 24 hours. Cells were then released
separately from the top of the membrane and the bottom of the
membrane. Transwell migration was then quantitated as the
percent of cells found on the underside of the membrane as de-
scribed [15]. All experiments were performed on parallel cultures
to control for variations in cell culture conditions.
Ex vivo effects of dietary MASL on cell migration
Mice (C57BL/6) were fed with a 200 mg food pellet containing
MASL to achieve doses of 0, 100, or 200 mg/kg 1 hour before
blood was taken from subclavian vein. Blood was allowed to
coagulate 1 hour at room temperature and clarified by centrifu-
gation for 10 minutes at 20,000 g to obtain serum. This serum was
added to cell culture medium (DMEM+10%FBS) to a final
concentration of 20%. B16 cell monolayers were scratched,
washed with DMEM, and then incubated with these media, or
control medium not fortified with mouse serum, for 24 hours to
assess their effects on cell migration by wound healing assays,
which were quantitated as the number of cells that entered an area
of the wound indicated in Figure Legends as described [15,84,85].
Use of mice to obtain serum was approved by Committee of
Animal Experiment in Nagoya University Graduate School of
Medicine (Approved ID: 23132).
In vivo tumorigenesis
Mice (C57BL/6) were fed with a 200 mg food pellet containing
MASL to achieve doses of 0 or 25 mg/kg once weekly, starting the
day before subcutaneous inoculation with 100,000 B16 cells in
0.1 ml PBS. Tumor volumes were measured blindly by a trained
physician with a single caliper daily. Mice were sacrificed 18 days
after inoculation and dissected. Tumors were fixed in formalin,
paraffin embedded, sectioned (5 microns), and processed for
hematoxylin/eosin staining or immunohistochemistry to detect
PDPN expression with 8.1.1 monoclonal antibody as described
[15,85,87]. Samples were analyzed on a Zeiss Axiovert microscope
with Axiovision software as described [15,85]. Mouse experimen-
tal protocols were approved by the UMDNJ-SOM Institutional
Animal Care and Use Committee (Approved ID: 10350).
MASL mass spectroscopy
MASL subunits were resolved by reducing and nonreducing
SDS-PAGE and stained by Coomassie dye. Bands were then
extracted and digested with trypsin. Extracted protein was reduced
and alkylated with iodoacetamide, and sequenced using data
dependent acquisition by LC-MS/MS on a Thermo Scientific
LTQ Orbitrap XL.
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